Paris, France ; Cambridge, Massachusetts (USA); October 18, 2022 – NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage biotechnology company pioneering physics-based approaches to expand treatment options for cancer patients, announces today that it has entered into a definitive agreement with the European Investment Bank (“EIB”) to structure the repayment schedule of its existing debt of approximately 30.7 million euros with a view to marketing and the conclusion of potential development agreements by the Company. Nanobiotix had previously announced, on September 12, 2022, the obtaining of an agreement in principle with the EIB for this restructuring.
The initial financing contract and the royalties agreement established with the EIB in July 2018 include a first tranche of 16 million euros paid in October 2018 and repayable in one installment at maturity in 2023, and a second tranche of 14 million euros paid in March 2019 and repayable in half-yearly installments in capital and interest at the end of a two-year period. The royalty agreement includes a commitment to pay annual royalties limited to a single digit (low end) over a period of six years from January 2021.